Hyperion Surgical, Inc. has announced the successful conclusion of the world”s first robotic-assisted intravenous (IV) catheterization using its innovative Ivy™ robotic vascular access platform. This groundbreaking achievement was made public on October 29, 2025, and represents a significant advancement in medical technology by combining imaging, artificial intelligence, and robotics to facilitate a no-touch approach to IV placements.
This pioneering procedure was conducted by the clinical team at Hyperion as part of a first-in-human (FIH) clinical study completed earlier this year. It signifies the initial clinical application of a robotic-assisted system designed for peripheral IV catheterization, which is recognized as the most frequently performed invasive procedure in medicine, with over 300 million IVs placed annually in the United States alone.
“No patient should ever be stuck more than once to place an IV. It”s long past time that we recognized that difficult-to-stick patients need a different paradigm,” stated Eric Peterson, MD, Founder and CEO of Hyperion Surgical. “Completing our first-in-human study represents the culmination of years of engineering, design, and clinical collaboration. We believe robotic and AI-assisted vascular access has the potential to deliver new levels of consistency, confidence, and predictability for clinicians and patients.”
The Ivy platform addresses a persistent challenge in the medical field—the significant variability and failure rate associated with IV placements. This system is engineered to insert the actual catheter into the blood vessel rather than merely placing the needle. The Ivy platform is poised to enhance IV therapy in various settings, including emergency, inpatient, and outpatient care environments.
Unlike existing technologies, Ivy serves as a semi-autonomous vascular access system that provides high-quality image guidance through direct, continuous visualization and artificial intelligence vessel recognition. It also features robotic insertion and stabilization capabilities. Traditional handheld devices necessitate considerable psychomotor skills to manually stabilize the ultrasound probe and needle continuously. In contrast, Ivy manages both the probe and needle for the user, executing the catheter insertion without any direct contact from the user. This no-touch technique aims to lower the cognitive and coordination demands typically required for image-guided IV placements.
“In certain demographics, difficult IV access can affect over 50% of patients. IV access presents daily challenges across all healthcare settings, where existing solutions often fall short in terms of reliability and consistency. It is also a source of frustration and discomfort for millions of patients,” commented Graham Snyder, MD, Medical Director of the Medical Simulation Center at WakeMed Health and Hospitals. “Given the prevalence of this issue, technologies that integrate imaging, automation, and robotics hold the promise of not only enhancing the patient experience but also achieving substantial quality improvements throughout the healthcare system.”
Following the successful completion of the first-in-human study, Hyperion is gearing up to submit its findings to the U.S. Food and Drug Administration (FDA) and is planning additional clinical evaluations to further explore the capabilities of the Ivy robotic vascular access platform. The company anticipates commencing commercialization within the next 18 months.
“Achieving the world”s first robotic-assisted IV catheterization is a landmark milestone for our team and partners,” Dr. Peterson remarked. “It validates our vision that intelligent automation can make vascular access more predictable, efficient, and ultimately more humane. Patients getting stuck multiple times just to place an IV is completely unacceptable.”
About Hyperion Surgical
Hyperion Surgical, Inc. is a medical technology firm that focuses on developing advanced robotic and AI-enabled systems to enhance precision, automation, and consistency in vascular access and interventional procedures. Based in Miami, the company is dedicated to making vascular access safer, faster, and more reliable for healthcare providers and patients globally. To learn more, follow Hyperion on LinkedIn and visit www.hyperionsurgical.com.
Media Contact:
Caren Begun
201-396-8551
[email protected]
Reference: Helm RE, Klausner JD, Klemperer JD, Flint LM, Huang E. Accepted but unacceptable: peripheral IV catheter failure. J Infus Nurs. 2015 May-Jun;38(3):189-203. doi: 10.1097/NAN.0000000000000100. PMID: 25871866.
